(VBK) VERBIO Vereinigte BioEnergie - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000A0JL9W6
Stock: Biofuels, Biogas, Chemicals, Feed
Total Rating 54
Risk 63
Buy Signal 0.26
| Risk 5d forecast | |
|---|---|
| Volatility | 69.1% |
| Relative Tail Risk | -11.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.16 |
| Alpha | 220.10 |
| Character TTM | |
|---|---|
| Beta | 0.586 |
| Beta Downside | 0.525 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.68% |
| CAGR/Max DD | -0.13 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy low_hurst
Description: VBK VERBIO Vereinigte BioEnergie March 05, 2026
VERBIO SE produces and distributes biofuels and related products globally. The company operates in Biodiesel, Bioethanol/Biomethane, and Other segments.
Its product portfolio includes biodiesel, biomethane, bioethanol, and pharma-glycerine. These are derived from agricultural raw materials. Biofuel production typically involves processing biomass into liquid or gaseous fuels.
VERBIO also offers animal feeds, phytosterols, and fertilizers. The company serves diverse sectors including oil, pharmaceuticals, transport, and agriculture. The renewable energy sector is experiencing growth due to increasing demand for sustainable alternatives.
For more detailed financial and operational data, ValueRay offers in-depth company analyses.
Headlines to watch out for
- Biofuel demand and pricing impact revenue
- Regulatory changes for renewable energy affect profitability
- Raw material costs for biodiesel and bioethanol fluctuate
- Global energy prices influence product competitiveness
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -112.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -0.55 > 1.0 |
| NWC/Revenue: 13.28% < 20% (prev 20.00%; Δ -6.72% < -1%) |
| CFO/TA 0.03 > 3% & CFO 43.3m > Net Income -112.2m |
| Net Debt (215.7m) to EBITDA (47.2m): 4.57 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.6m) vs 12m ago 14.19% < -2% |
| Gross Margin: 6.98% > 18% (prev 0.16%; Δ 682.8% > 0.5%) |
| Asset Turnover: 128.8% > 50% (prev 107.5%; Δ 21.25% > 0%) |
| Interest Coverage Ratio: -4.79 > 6 (EBITDA TTM 47.2m / Interest Expense TTM 18.0m) |
Altman Z'' 1.76
| A: 0.18 (Total Current Assets 532.2m - Total Current Liabilities 303.4m) / Total Assets 1.28b |
| B: 0.15 (Retained Earnings 197.0m / Total Assets 1.28b) |
| C: -0.06 (EBIT TTM -86.4m / Avg Total Assets 1.34b) |
| D: 0.49 (Book Value of Equity 260.7m / Total Liabilities 533.3m) |
| Altman-Z'' Score: 1.76 = BBB |
Beneish M -2.40
| DSRI: 1.02 (Receivables 106.5m/91.5m, Revenue 1.72b/1.50b) |
| GMI: 2.23 (GM 6.98% / 15.55%) |
| AQI: 0.20 (AQ_t 0.00 / AQ_t-1 0.02) |
| SGI: 1.15 (Revenue 1.72b / 1.50b) |
| TATA: -0.12 (NI -112.2m - CFO 43.3m) / TA 1.28b) |
| Beneish M-Score: -2.40 (Cap -4..+1) = BBB |
What is the price of VBK shares?
As of March 11, 2026, the stock is trading at EUR 31.16 with a total of 268,307 shares traded.
Over the past week, the price has changed by +20.68%, over one month by +33.28%, over three months by +56.74% and over the past year by +228.00%.
Over the past week, the price has changed by +20.68%, over one month by +33.28%, over three months by +56.74% and over the past year by +228.00%.
Is VBK a buy, sell or hold?
VERBIO Vereinigte BioEnergie has no consensus analysts rating.
What are the forecasts/targets for the VBK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.7 | -53% |
| Analysts Target Price | - | - |
VBK Fundamental Data Overview March 07, 2026
Market Cap USD = 1.28b (1.12b EUR * 1.1513 EUR.USD)
P/E Forward = 6.7385
P/S = 1.0191
P/B = 2.2887
P/EG = 5.8004
Revenue TTM = 1.72b EUR
EBIT TTM = -86.4m EUR
EBITDA TTM = 47.2m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 94.9m EUR (from shortTermDebt, last quarter)
Debt = 287.2m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 215.7m EUR (from netDebt column, last quarter)
Enterprise Value = 1.32b EUR (1.12b + Debt 287.2m - CCE 86.0m)
Interest Coverage Ratio = -4.79 (Ebit TTM -86.4m / Interest Expense TTM 18.0m)
EV/FCF = -18.78x (Enterprise Value 1.32b / FCF TTM -70.1m)
FCF Yield = -5.33% (FCF TTM -70.1m / Enterprise Value 1.32b)
FCF Margin = -4.07% (FCF TTM -70.1m / Revenue TTM 1.72b)
Net Margin = -6.52% (Net Income TTM -112.2m / Revenue TTM 1.72b)
Gross Margin = 6.98% ((Revenue TTM 1.72b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 17.38% (prev 13.21%)
Tobins Q-Ratio = 1.03 (Enterprise Value 1.32b / Total Assets 1.28b)
Interest Expense / Debt = 0.80% (Interest Expense 2.30m / Debt 287.2m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -64.8m (EBIT -86.4m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.75 (Total Current Assets 532.2m / Total Current Liabilities 303.4m)
Debt / Equity = 0.39 (Debt 287.2m / totalStockholderEquity, last quarter 742.8m)
Debt / EBITDA = 4.57 (Net Debt 215.7m / EBITDA 47.2m)
Debt / FCF = -3.08 (negative FCF - burning cash) (Net Debt 215.7m / FCF TTM -70.1m)
Total Stockholder Equity = 776.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.39% (Net Income -112.2m / Total Assets 1.28b)
RoE = -14.46% (Net Income TTM -112.2m / Total Stockholder Equity 776.0m)
RoCE = -9.10% (EBIT -86.4m / Capital Employed (Equity 776.0m + L.T.Debt 173.4m))
RoIC = -6.29% (negative operating profit) (NOPAT -64.8m / Invested Capital 1.03b)
WACC = 6.54% (E(1.12b)/V(1.40b) * Re(8.07%) + D(287.2m)/V(1.40b) * Rd(0.80%) * (1-Tc(0.25)))
Discount Rate = 8.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -8.32%
[DCF] Fair Price = unknown (Cash Flow -70.1m)
EPS Correlation: -87.58 | EPS CAGR: -17.58% | SUE: -0.10 | # QB: 0
Revenue Correlation: -52.22 | Revenue CAGR: 1.65% | SUE: 1.76 | # QB: 1
EPS current Year (2026-06-30): EPS=0.07 | Chg7d=+0.027 | Chg30d=+0.027 | Revisions Net=-1 | Growth EPS=+103.2% | Growth Revenue=+11.2%
EPS next Year (2027-06-30): EPS=0.74 | Chg7d=-0.005 | Chg30d=-0.052 | Revisions Net=-3 | Growth EPS=+969.0% | Growth Revenue=+13.0%
P/E Forward = 6.7385
P/S = 1.0191
P/B = 2.2887
P/EG = 5.8004
Revenue TTM = 1.72b EUR
EBIT TTM = -86.4m EUR
EBITDA TTM = 47.2m EUR
Long Term Debt = 173.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 94.9m EUR (from shortTermDebt, last quarter)
Debt = 287.2m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 215.7m EUR (from netDebt column, last quarter)
Enterprise Value = 1.32b EUR (1.12b + Debt 287.2m - CCE 86.0m)
Interest Coverage Ratio = -4.79 (Ebit TTM -86.4m / Interest Expense TTM 18.0m)
EV/FCF = -18.78x (Enterprise Value 1.32b / FCF TTM -70.1m)
FCF Yield = -5.33% (FCF TTM -70.1m / Enterprise Value 1.32b)
FCF Margin = -4.07% (FCF TTM -70.1m / Revenue TTM 1.72b)
Net Margin = -6.52% (Net Income TTM -112.2m / Revenue TTM 1.72b)
Gross Margin = 6.98% ((Revenue TTM 1.72b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 17.38% (prev 13.21%)
Tobins Q-Ratio = 1.03 (Enterprise Value 1.32b / Total Assets 1.28b)
Interest Expense / Debt = 0.80% (Interest Expense 2.30m / Debt 287.2m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -64.8m (EBIT -86.4m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.75 (Total Current Assets 532.2m / Total Current Liabilities 303.4m)
Debt / Equity = 0.39 (Debt 287.2m / totalStockholderEquity, last quarter 742.8m)
Debt / EBITDA = 4.57 (Net Debt 215.7m / EBITDA 47.2m)
Debt / FCF = -3.08 (negative FCF - burning cash) (Net Debt 215.7m / FCF TTM -70.1m)
Total Stockholder Equity = 776.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.39% (Net Income -112.2m / Total Assets 1.28b)
RoE = -14.46% (Net Income TTM -112.2m / Total Stockholder Equity 776.0m)
RoCE = -9.10% (EBIT -86.4m / Capital Employed (Equity 776.0m + L.T.Debt 173.4m))
RoIC = -6.29% (negative operating profit) (NOPAT -64.8m / Invested Capital 1.03b)
WACC = 6.54% (E(1.12b)/V(1.40b) * Re(8.07%) + D(287.2m)/V(1.40b) * Rd(0.80%) * (1-Tc(0.25)))
Discount Rate = 8.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -8.32%
[DCF] Fair Price = unknown (Cash Flow -70.1m)
EPS Correlation: -87.58 | EPS CAGR: -17.58% | SUE: -0.10 | # QB: 0
Revenue Correlation: -52.22 | Revenue CAGR: 1.65% | SUE: 1.76 | # QB: 1
EPS current Year (2026-06-30): EPS=0.07 | Chg7d=+0.027 | Chg30d=+0.027 | Revisions Net=-1 | Growth EPS=+103.2% | Growth Revenue=+11.2%
EPS next Year (2027-06-30): EPS=0.74 | Chg7d=-0.005 | Chg30d=-0.052 | Revisions Net=-3 | Growth EPS=+969.0% | Growth Revenue=+13.0%